Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57
Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.
Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200
Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.
Truist Securities Maintains Buy on Wingstop, Lowers Price Target to $130
Truist Securities analyst Jake Bartlett maintains Wingstop (NASDAQ:WING) with a Buy and lowers the price target from $160 to $130.
Wells Fargo Maintains Overweight on Corporate Office Props Tr, Lowers Price Target to $30
Wells Fargo analyst Blaine Heck maintains Corporate Office Props Tr (NYSE:OFC) with a Overweight and lowers the price target from $33 to $30.
Needham Maintains Buy on Outbrain, Lowers Price Target to $7
Needham analyst Laura Martin maintains Outbrain (NASDAQ:OB) with a Buy and lowers the price target from $10 to $7.
Mizuho Maintains Buy on Mastercard, Lowers Price Target to $375
Mizuho analyst Dan Dolev maintains Mastercard (NYSE:MA) with a Buy and lowers the price target from $435 to $375.
Wells Fargo Maintains Equal-Weight on M&T Bank, Lowers Price Target to $175
Wells Fargo analyst Christopher Spahr maintains M&T Bank (NYSE:MTB) with a Equal-Weight and lowers the price target from $195 to $175.
Endo Posts Disappointing Data From Frozen Shoulder Trial
Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with…
Wells Fargo Maintains Overweight on U.S. Bancorp, Lowers Price Target to $60
Wells Fargo analyst Mike Mayo maintains U.S. Bancorp (NYSE:USB) with a Overweight and lowers the price target from $70 to $60.
Wells Fargo Maintains Overweight on Goldman Sachs Group, Lowers Price Target to $380
Wells Fargo analyst Mike Mayo maintains Goldman Sachs Group (NYSE:GS) with a Overweight and lowers the price target from $420 to $380.